Merck Collaborating With Canadian Company Neuromed For Chronic Pain Treatment

22Mar06

Merck will be collaborating with Neuromed to develop new treatments for chronic pain. The deal includes Neuromed’s leading compound NMED-160, currently mid-way through testing.

These do sound quite hopeful, as Christopher Gallun, the CEO of Neuromed told the New York Times in an interview “We think these have the potential to become very powerful agents for chronic pain, on the level of morphine,”. The mechanism of action of this painkiller is not new, but the side-effect profile should be significantly lower than what’s available now from that class of medication.

The deal is being described as one of the richest collaborations ever in this country. Neuromed is a biotech spin-off from the University of British Columbia, set up by UBC Professor Terrance Snutch in 1998. See stories from The Vancouver Sun and The New York Times for further details.

Advertisements


2 Responses to “Merck Collaborating With Canadian Company Neuromed For Chronic Pain Treatment”

  1. 1 goo.gl

    Thanks , I have just been looking for information approximately this subject for ages and yours
    is the greatest I’ve discovered till now. However, what concerning the bottom line? Are you certain about the supply?

  2. Thanks for finally writing about >Merck Collaborating With Canadian Company Neuromed For
    Chronic Pain Treatment | better days <Liked it!


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: